Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abivax SA
The French biotech has been making steady progress in raising the funds needed to advance obefazimod and this week has seen new equity backers Kreos, Claret and Heights come onboard.
Abivax has had its ups and downs but newly appointed CEO Marc de Garidel tells Scrip he is confident that the French group is onto a winner with its ulcerative colitis drug, obefazimod.
The French biotech has attracted a raft of new US healthcare specialist backers in one of the biggest raises ever on the Euronext Paris but it will need millions more to complete the late-stage program for obefazimod.
The French biotech is pleased to have raised nearly €50m considering the "currently very challenging financing environment," but it will need to find €150m more to complete last-stage trials of obefazimod in ulcerative colitis.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.